Bacteriophage Market Analysis, By Product Type (Phage Probiotics, Phage Therapeutics), By Route of Administration (Oral, Tropical, Others), By Application and By Distribution Channel - Global Market Insights 2022 to 2032
Analysis of Bacteriophage market covering 30 + countries including analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Bacteriophage Market Outlook (2022-2032)
The global bacteriophage market has reached a valuation of US$ 43.2 Mn and is forecasted to expand at a CAGR of 5.3% to climb to US$ 72.1 Mn by the end of 2032.
Use of bacteriophages as probiotics will guide more than 70% increase in the global market over the next ten years.
Bacteriophage Market Size (2021A)
US$ 41.5 Mn
Estimated Market Value (2022E)
US$ 43.2 Mn
Forecasted Market Value (2032F)
US$ 72.1 Mn
Global Market Growth Rate (2022-2032)
5.3 % CAGR
North America Market Share (2021)
East Asia Market Growth Rate (2022-2032)
7.7 % CAGR
United States Market Growth Rate (2022-2032)
4.1 % CAGR
Market Share of Top 5 Companies
Key Companies Profiled
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Bacteriophage Sales Analysis (2017-2021) Vs. Market Forecasts (2022-2032)
Bacteriophage has been in high demand among end users who suffer from bacterial infections. Key industry players’ objective of producing bacteriophage dietary supplements for a healthy gut has helped them maintain a prominent position in the healthcare sector. Increasing cases of urinary tract infections and dysentery have contributed a great extent to the use of bacteriophage therapy among patients.
Utilization of phage probiotics by end users increased at a compound annual growth rate of 3.5% from 2017 to 2021.
The prevalence of food-borne infections is on the rise. Consumption of phage probiotics promotes the growth of good bacteria over bad bacteria and maintains a balance between the two, which promotes a healthy lifestyle among individuals and will majorly contribute to market growth.
Fact.MR predicts that the global bacteriophage market will be valued at US$ 72.1 million by 2032-end.
- Short Term (2022 Q2 to 2025): Bacteriophage therapies to be used for the treatment and prevention of antibiotic resistance, positively impacting market growth.
- Medium Term (2025-2028): Rising awareness about the beneficial factors of bacteriophage therapy to drive product demand.
- Long Term (2028-2032): Investments in R&D sector to positively drive the long-term expansion of the target market.
According to Fact.MR, a market research and competitive intelligence provider, the market for bacteriophages is projected to exhibit growth at 5.3% CAGR from 2022 to 2032.
Market share analysis of bacteriophage based on region and product type. Under product type, phage probiotics dominate with 95.4% market share in 2022.
Why is Demand for Bacteriophage Set to Increase Steadily?
“Rising Consumer Awareness about Healthy Gut Microbiome”
Nowadays, consumers’ interest is skewed towards products with associated health benefits. Hence, there has been a shift towards more conventional treatments, thereby driving the sales of bacteriophages.
The prevalence of gastrointestinal symptoms is on the rise due to changing and hectic lifestyles of the population. Bacteriophages are known to preserve healthy bacteria in the stomach, which, in turn, facilitates better digestion, regular bowel movements, and reduced intestinal inflammation. Bacteriophage is thus well acknowledged by consumers as pre/probiotic dietary supplements.
“Availability of Bacteriophage Products via e-Commerce Platforms”
Bacteriophage consumed as pre/probiotic has been segmented under the category of dietary supplements, and is readily available not only in pharmacies and medical dispensaries but also in supermarkets and hypermarkets. With the development in technology and its adoption by the population, digitalization has become a part of our everyday life, with e-Commerce platforms gaining more preference.
The availability of bacteriophage-based products via online channels will not only provide manufacturers with better customer outreach but will also result in global recognition of products, thereby increasing their demand. In addition, consumers get the opportunity to select from a variety of options according to their requirements.
This omnipresence of products on all sales platforms will increase market demand substantially over the coming years.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
What Issue Do Bacteriophage Producers Need to Contend With?
“Exorbitant Rates of Bacteriophage Products Hurting Market Stance”
Bacteriophage is widely used as a dietary supplement in the form of pre/probiotic supplements. Despite the associated medical benefits, bacteriophage products and therapies still face a setback in the market as a trade-off of the high cost and limited consumer affordability.
Expensive machinery and processing have been the key challenges for manufacturers. The high cost of production and investments in the R&D sector for the production of bacteriophages cannot be met by all manufacturers, and also affects the final price of the product, thereby reducing its consumer reach.
Why is Europe a Major Market for Bacteriophage Suppliers?
The bacteriophage market in Europe is expected to reach US$ 28.5 million by 2032.
A transition in consumers’ desire towards a healthy lifestyle has led to an increase in demand for preventative healthcare. It has also motivated manufacturers to develop new functional products that help maintain a healthy lifestyle in various forms according to customer requirements. Consequently, this opens up a sizable market for the bacteriophage industry.
With stringent regulations associated with the production of products in the healthcare sector, quality bacteriophage products are offered to end users, thereby increasing its sales in Europe. In addition, European governments are actively supporting the efforts of manufacturers to produce health-benefiting products, which, in turn, has led to increased demand for bacteriophage products and therapies in the region.
Will the East Asia Bacteriophage Market Be Lucrative for Industry Players?
East Asia, representing key developing economies, will always have an incremental scope for these products as regional consumers are open to developing technologies and consequent innovative and beneficial products.
Moreover, the increase in the per capita healthcare spending of the population has opened a plethora of opportunities for bacteriophage suppliers in East Asia. The attentiveness of consumers can create an extensive opportunity for key manufacturers as well as new emerging market players in the region.
The East Asia bacteriophage market is currently valued at US$ 3.4 million.
Will the Oral Route of Administration Continue Governing Bacteriophage Therapy?
Among the various drug-delivery routes, the oral route has attracted the most people as a convenient way to deliver various therapeutic agents. Factors such as controlled delivery, ease of administration, non-invasiveness, cost-effectiveness, etc., have increased the use of orally administered phages among patients. The compliance of patients to orally administered formulations is usually higher in comparison to other forms of administration. In addition, orally administered phage therapy can be targeted to a specific region for localized treatment as well.
Thus, the oral route of administration for bacteriophage therapy has increased steadily in the recent past, reaching a market valuation of US$ 40.1 million in 2021.
How is Gastroenterology Driving Market Expansion?
Today, sales of bacteriophages for various applications by commercial end users are increasing rapidly. The prevalence of gastrointestinal disorders and symptoms was observed to be significantly higher during the COVID-19 pandemic than under normal circumstances. The opportunity to prevent and treat gastrointestinal disorders with the use of bacteriophage therapy will drive market growth during the assessment period.
Use of bacteriophage therapy for gastroenterology is anticipated to create an absolute $ opportunity of US$ 1.7 million by the end of the assessment period of 2022-2032.
Prominent bacteriophage manufacturers are Life Extension, Arthur Andrew Medical, ADM, Biochimpharm, Micreos Human Health, and Probiotic America.
Rising prevalence of antibiotic resistance and limited discoveries of new antibiotics in the market are major factors compelling key market players to develop bacteriophage therapy products. Manufacturers are extending their consumer reach with mergers and partnerships. Robust R&D and new product launches that address the existing concerns of end users are being witnessed in this space.
- In Nov 2021, ADM acquired U.S.-based Deerland Probiotics and Enzymes, which specializes in developing dietary supplements that benefit human microbe health.
- In August 2021, Intralytix was awarded a Fast Track NIH SBIR contract to create a global scale-independent AI-based platform for producing high titer bacteriophage preparations for clinical applications.
Fact.MR has provided detailed information about the price points of key manufacturers of bacteriophages positioned across regions, sales growth, production capacity, and speculative technological expansion, in the recently published report.
Segmentation of Bacteriophage Industry Research
By Product Type :
- Phage Probiotics
- Phage Therapeutics
By Route of Administration :
By Application :
- Respiratory Infections Treatment
- Skin Infection Treatment
- Wound Prophylaxis
- Urogenital Infection Treatment
By Distribution channel :
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
By Region :
- North America
- Latin America
- East Asia
- South Asia & Oceania
- FAQs -
The global bacteriophage market is currently valued at US$ 43.2 million.
Worldwide demand for bacteriophages is anticipated to reach US$ 72.1 million by 2032.
From 2017 to 2021, sales of bacteriophages increased at 3.6% CAGR.
Europe leads the global bacteriophage market accounting for 42.6% share in 2022.
Oral route administration of bacteriophage therapy accounts for 96.9% market share.